BridgeBio Pharma Inc. has entered into a significant financial agreement involving the sale of royalty interests. On June 27, 2025, BridgeBio and its subsidiary Eidos Therapeutics, Inc. finalized a Royalty Interest Purchase and Sale Agreement with Acoramidis Royalty SPV, LP and LSI Financing Fund, LP. This agreement involves Eidos selling certain royalty payment rights from net sales of products containing acoramidis in the European Union and related territories. In exchange, the purchasers have agreed to pay Eidos $300 million in cash. The purchasers' rights are capped annually at 60% of royalty payments from Bayer and include an initial hard cap of 145% of the purchase price. This arrangement is secured by specific assets and includes standard representations, warranties, and indemnification obligations.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。